Clinical Trial Update: Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating Fluzoparib in combination with Chidamide or Camrelizumab for HRD-positive, HER2-negative advanced breast cancer is underway,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hrd-positive Breast Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)
• Chidamide (chidamide)
• Fluzoparib (fluzoparib)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Advanced HER2 Negative Breast Carcinoma, HRD+Breast Cancer | Phase 2 | Status: UNKNOWN